Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?
Ovarian cancer is one of the most lethal gynaecological malignancies worldwide. Despite high success rates following first time treatment, this heterogenous disease is prone to recurrence. Oncogenic activity of receptor tyrosine kinases is believed to drive the progression of ovarian cancer. Here we...
Main Authors: | Aimee Rendell, Isobel Thomas-Bland, Lee McCuish, Christopher Taylor, Mudra Binju, Yu Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/10/9/2113 |
Similar Items
-
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
by: Qinlian Jiao, et al.
Published: (2018-02-01) -
The function of TTK1 in platinum-resistant ovarian cancer
by: LIU Yixuan , WEN Zexuan , GUO Lin , LU Renquan
Published: (2021-03-01) -
Sulfonamides as tyrosine kinase modulators – A promising class of anticancer agents
by: Rudradip Das, et al.
Published: (2023-01-01) -
Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01) -
Nonreceptor Tyrosine Kinases in Prostate
by: Cancer Yu-Ming Chang, et al.
Published: (2007-02-01)